Sign in

Roger A. Jeffs

Chief Executive Officer at Liquidia
Board
Since January 2022
Age
63 years
Education
Holds a Ph.D., although details regarding the institutions or field of study are not provided.
Tenure
Joined LQDA as a Board Member in November 2020 and began serving as Chief Executive Officer in January 2022.

Also at Liquidia

JA
Jason Adair
Chief Business Officer
MK
Michael Kaseta
Chief Operating Officer (COO)
RS
Rajeev Saggar
Chief Medical Officer

About

Roger A. Jeffs, Ph.D. is the Chief Executive Officer of Liquidia Corporation (LQDA), having assumed the role in January 2022 after initially joining as a Board Member in November 2020.

With an extensive background in the biotechnology and pharmaceutical sectors, he has previously held senior roles at United Therapeutics Corporation, where he contributed to the commercialization and development of multiple pharmaceutical products over an 18-year career. His leadership experience spans roles including President, Chief Operating Officer, and co-CEO, which underscores his proficiency in managing large-scale, growth-oriented organizations.

At LQDA, his strategic oversight is complemented by his participation in various committees, including Compensation, Research and Development, and Litigation, reflecting his commitment to robust corporate governance and operational excellence.

$LQDA Performance Under Roger A. Jeffs

Past Roles

OrganizationRoleDate RangeDetails
Liquidia Corporation Research and Development Committee Member April 2021 - January 2022 Served on R&D Committee
Liquidia Corporation Litigation Committee Member April 2021 - January 2022 Served on Litigation Committee
Liquidia Corporation Compensation Committee Member November 2020 - December 2021 Served on Compensation Committee
Liquidia Corporation Board Member November 2020 - January 2022 Appointed as condition to merger transaction
RareGen Director August 2018 - November 2020 Merged with Liquidia
United Therapeutics Corporation Director of Research, Development, and Medical 1998 - 2001 Joined during inception phase
United Therapeutics Corporation President and Chief Operating Officer 2001 - 2014 Oversaw clinical development and regulatory approval
United Therapeutics Corporation President and co-CEO 2015 - 2016 Helped lead IPO and managed commercial effort
United Therapeutics Corporation Board Member 2001 - 2016 Served on board during tenure
Amgen, Inc. Clinical development roles N/A Held various roles in clinical development
Burroughs Wellcome Co. Clinical development roles N/A Held roles in clinical development

External Roles

OrganizationRoleDate RangeDetails
Kriya Therapeutics Co-Founder and Vice Chairman Since October 2019 Gene therapy company
Axsome Therapeutics, Inc. (Nasdaq: AXSM) Board Member N/A Biopharmaceutical company

Fixed Compensation

Data from  FY 2024
Component NameAmount (USD)Payment ScheduleAdditional Details
Salary$800,000 Annually Base salary for fiscal year 2024
Stock Awards$5,533,450 Annually Granted as restricted stock units per ASC Topic 718
All Other Compensation$14,580 Per-payroll Contributions to 401(k) plan and health savings account

Performance Compensation

Data from  FY 2024

No information available on performance compensation for 2024